---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-159886"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2025-07-16T23:59:59+00:00"
generated_at: "2026-05-18T06:15:36.931052+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Quince completes Phase 3 NEAT enrollment with 105 patients; topline results Q1 2026

## Summary
- Enrolled 105 participants total; 83 in primary analysis (ages 6-9), 22 aged 10+.
- Powering at ~90% for primary endpoint; trial under FDA Special Protocol Assessment.
- Topline results expected Q1 2026; NDA submission planned H2 2026 if positive.
- All enrolled participants have elected to transition to open-label extension study.
- FDA Fast Track designation and SPA agreement in place for eDSP in Ataxia-Telangiectasia.

## SEC filing metadata
- accession: 0001193125-25-159886
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2025-07-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312525159886/0001193125-25-159886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312525159886/d71020d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-159886
- JSON: https://secwatch.observer/filing/0001193125-25-159886.json
- Plain text: https://secwatch.observer/filing/0001193125-25-159886.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.